The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment

Pierre Poitras; Marie-Hélène Gingras; Jens F Rehfeld

doi:10.1016/j.cgh.2011.08.012

The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment

Pierre Poitras, Marie-Hélène Gingras, Jens F Rehfeld

Department of Clinical Biochemistry

62 Citations (Scopus)

Abstract

Patients with Zollinger-Ellison syndrome (ZES) are treated by proton pump inhibitors (PPIs) to protect them from severe and potentially lethal peptic complications related to massive gastric acid hypersecretion. We report here on the dangerous consequences of interrupting PPI therapy.

Original language	English
Journal	Clinical Gastroenterology and Hepatology
Volume	10
Issue number	2
Pages (from-to)	199-202
Number of pages	4
ISSN	1542-3565
DOIs	https://doi.org/10.1016/j.cgh.2011.08.012
Publication status	Published - 2012

Keywords

Esophageal Stenosis
Humans
Intestinal Perforation
Male
Middle Aged
Proton Pump Inhibitors
Withholding Treatment
Zollinger-Ellison Syndrome

Access to Document

10.1016/j.cgh.2011.08.012

Cite this

@article{2f92c2ccbf1745dfa8feba94171d4784,

title = "The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment",

abstract = "Patients with Zollinger-Ellison syndrome (ZES) are treated by proton pump inhibitors (PPIs) to protect them from severe and potentially lethal peptic complications related to massive gastric acid hypersecretion. We report here on the dangerous consequences of interrupting PPI therapy.",

keywords = "Esophageal Stenosis, Humans, Intestinal Perforation, Male, Middle Aged, Proton Pump Inhibitors, Withholding Treatment, Zollinger-Ellison Syndrome",

author = "Pierre Poitras and Marie-H{\'e}l{\`e}ne Gingras and Rehfeld, \{Jens F\}",

year = "2012",

doi = "10.1016/j.cgh.2011.08.012",

language = "English",

volume = "10",

pages = "199--202",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders",

number = "2",

}

TY - JOUR

T1 - The Zollinger-Ellison syndrome

T2 - dangers and consequences of interrupting antisecretory treatment

AU - Poitras, Pierre

AU - Gingras, Marie-Hélène

AU - Rehfeld, Jens F

PY - 2012

Y1 - 2012

N2 - Patients with Zollinger-Ellison syndrome (ZES) are treated by proton pump inhibitors (PPIs) to protect them from severe and potentially lethal peptic complications related to massive gastric acid hypersecretion. We report here on the dangerous consequences of interrupting PPI therapy.

AB - Patients with Zollinger-Ellison syndrome (ZES) are treated by proton pump inhibitors (PPIs) to protect them from severe and potentially lethal peptic complications related to massive gastric acid hypersecretion. We report here on the dangerous consequences of interrupting PPI therapy.

KW - Esophageal Stenosis

KW - Humans

KW - Intestinal Perforation

KW - Male

KW - Middle Aged

KW - Proton Pump Inhibitors

KW - Withholding Treatment

KW - Zollinger-Ellison Syndrome

UR - https://www.scopus.com/pages/publications/84856038551

U2 - 10.1016/j.cgh.2011.08.012

DO - 10.1016/j.cgh.2011.08.012

M3 - Journal article

C2 - 21871248

SN - 1542-3565

VL - 10

SP - 199

EP - 202

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 2

ER -

The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this